Equities

Cannasouth Ltd

CBD:NZC

Cannasouth Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NZD)0.098
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change-52.40%
  • Beta0.7852
Data delayed at least 20 minutes, as of Mar 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.

  • Revenue in NZD (TTM)955.55k
  • Net income in NZD-8.81m
  • Incorporated2018
  • Employees--
  • Location
    Cannasouth Ltd240 Victoria StreetLevel 1, Hamilton CentralHamilton 3216New ZealandNZL
  • Phone+64 79498393
  • Websitehttps://www.cannasouth.co.nz/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Noxopharm Ltd4.33m-13.46m24.00m1.00k--3.29--5.54-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Supergenics Bhd3.69m63.83k25.05m9.00320.867.4360.496.780.00190.00190.10860.08070.586915.721.22--0.8456-1.021.37-1.5745.4133.881.44-1.421.862.700.3717---4.478.99-48.85-34.94143.02--
Tryptamine Therapeutics Ltd1.34m-4.79m25.38m----3.40--18.94-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
LBT Innovations Limited2.22m-23.72m27.80m17.00--7.90--12.50-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Invion Ltd4.95m-1.66m29.32m8.00--1.44--5.92-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
Cannasouth Ltd955.55k-8.81m32.39m----0.6699--33.89-0.0352-0.03530.00440.14630.0261.673.33---23.95-25.58-26.28-27.74-127.65---921.78-1,678.991.06-80.140.0913--579.62---11.15------
Biotron Ltd1.83m-4.46m33.04m4.00--15.93--18.10-0.0045-0.00450.00180.00210.3587-------87.73-64.30-103.46-74.43-156.30-108.03-244.54-231.62----0.0148---8.16-2.48-25.59------
D.Western Therapeutics Institute Inc4.86m-11.35m33.92m21.00--2.95--6.98-32.29-32.2913.8429.840.17840.4723.1021,103,950.00-42.16-13.06-45.11-14.3691.3294.29-236.36-72.5111.65--0.509---4.407.90-89.07--7.08--
Prescient Therapeutics Ltd774.56k-8.59m40.22m3.00--1.60--51.92-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Data as of Mar 25 2024. Currency figures normalised to Cannasouth Ltd's reporting currency: New Zealand Dollar NZD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.